5717-17-9

Upstream product

• 91541-28-5 4-(4-Methoxy-phenyl)-3-methyl-4-oxo-butyric acid methyl ester 
• 100-66-3 methoxybenzene 
• 4100-80-5 2-methylsuccinic anhydride 
• 340825-90-3 4-(4-methoxy-phenyl)-3-methyl-butyric acid 
• 7732-18-5 water 
• 1060738-54-6 C₁₆H₂₂O₄ 
• 3724-65-0 2-butenoic acid 
• 123-11-5 4-methoxy-benzaldehyde 
• 121-97-1 4-Methoxypropiophenone 
• 21086-33-9 2-bromo-1-(4-methoxyphenyl)-1-propanone 
• 539820-72-9 ethyl 2-ethoxycarbonyl-3-(4-methoxybenzoyl)butanoate 

Downstream Products

• 539820-74-1 6-(4-methoxyphenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one 
• 264907-10-0 4-methyl-5-(4-methoxyphenyl)dihydrofuran-2(3H)-one 
• 106192-14-7 (RS,SR)-γ-hydroxy-γ-(4-methoxyphenyl)-β-methylbutanoic acid lactone 
• 103416-88-2 6-(4-hydroxyphenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one 

Relevant academic research and scientific papers

Bio-based crotonic acid from polyhydroxybutyrate: synthesis and photocatalyzed hydroacylation

A novel thermolytic distillation process was developed to depolymerize polyhydroxybutyrate (PHB) for the selective production of crotonic acid. The conditions adopted (170 °C, 150 mbar) were applied to pure PHB and PHB-enriched bacteria containing 60 and 30% of PHB, giving a recovery of crotonic acid of 92, 78 and 58%, respectively. The high efficiency of the developed process poses the basis for a drop-in production of bio-based crotonic acid, whose versatility as a platform chemical has been investigated through a photochemical approach. The photocatalytic addition (promoted by tetrabutylammonium decatungstate - TBADT) of aliphatic and aromatic aldehydes to crotonic acid took place under solar-simulated light irradiation. TBADT triggered thein situformation of valuable acyl radicals from the corresponding aldehydes, thus inducing the desired hydroacylationviaradical conjugate addition. Notably, the functionalization took place in a satisfactory yield quite independently of the adopted sample of crotonic acid (whether commercial or bio-based).

Catalytic Redox Chain Ring Opening of Lactones with Quinones to Synthesize Quinone-Containing Carboxylic Acids

Catalytic ring opening of five- to eight-membered lactones with quinones is achieved through a redox chain mechanism. With low loading of a simple metal triflate Lewis acid catalyst and a chain initiator, C-H bonds of many quinones were efficiently functionalized with carboxylic acid-containing side chains. This method also features 100% atom economy and wide substrate scope. A novel route to the anti-asthma drug Seratrodast was developed. Mechanism study suggests that the redox chain reaction likely undergoes a carbocation intermediate.

PYRIDAZINONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyridazinone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1 represents H or C1-6 alkyl, each of R2 and R3 represents H, X, C1-6 alkoxy, Z represents O or S, and A represents AA or BB, wherein AA represents: and BB represents: wherein R4 represents H or C1-6 alkyl, and each of R5 and R6 represents C1-6 alkyl.

PYRAZOLONE DERIVATIVE AND PDE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT

It is to provide a novel pyrazolone derivative represented by the following general formula (1), which is useful as a pharmaceutical and has a phosphodiesterase inhibitory action: wherein R1,R2: C1-6 alkyl; R3,R4: H, X, C1-6 alkoxy; Z:O, S; A:AA, BB, wherein AA represents wherein BB represents wherein R5: H, C1-6 alkyl ; R6,R7: C1-6 alkyl.

Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids: A novel series of potent dual PDE3/PDE4 inhibitory agents

In this study, the synthesis and in vitro and in vivo pharmacological investigations of a new series of phthalazinone/pyridazinone hybrids with both PDE3 and PDE4 inhibitory activities are described. These compounds combine the pharmacophores of recently discovered 4a,5,8,-8a-tetrahydro-2H-phthalazin-1-one-type inhibitors of PDE4 and the well-known 2H-pyridazin-3-one-type PDE3 inhibitors such as the tetrahydrobenzimidazoles. Most of the synthesized compounds are pharmacologically spoken PDE3/PDE4 hybrids. All hybrids show potent PDE4 inhibitory activity (pIC50 = 7.0-8.7), whereas the pIC50 values for inhibition of PDE3 vary from 5.4 to 7.5. In general, analogues with a 5-methyl-4,5-dihydropyridazinone moiety exhibit the highest PDE3 inhibitory activities. The highest in vivo antiinflammatory activity is displayed by phthalazinones 43 and 44 showing, at a dose of 30μmol/kg po, 46% inhibition of arachidonic acid (AA) induced mouse ear edema. No correlation was found between the in vitro PDE3 and/or PDE4 inhibitory activity and the in vivo antiinflammatory capacity after oral dosing.

Acylation of anisole with methylsuccinic anhydride catalysed by zeolites

The zeolite-catalysed acylation of anisole with methylsuccinic anhydride gave a mixture of products. The main component was 4-hydroxy-4,4-bis-(4-methoxyphenyl)-2-methyl-γ-butyrolactone, which was isolated in 25% yield; the expected keto acids were not for

Process for the production of cyclic sulfonium salts

A process for the production of a 5-7 membered ring cyclic sulfonium salt compound, including a 5-7 membered ring cyclic sulfonium salt compound having a non-nucleophilic anion, is described. Members of the latter group are potentially useful as initiators for cationic polymerizations. The process comprises reacting a 1.4-, 1.5-, or 1.6-diol compound or a 5-7 membered ring cyclic ether compound with a mercapto compound and a strong protonic acid yielding the cyclic sulfonium salt compound. Some compounds described are also novel compounds per se.